S&P Futures
3,928.25 +30.50 (+0.78%) Dow Futures
31,394.00 +192.00 (+0.62%) Nasdaq Futures
12,004.25 +126.00 (+1.06%) Russell 2000 Futures
1,793.10 +18.20 (+1.03%) Crude Oil
110.85 -1.36 (-1.21%) Gold
1,842.00 +0.80 (+0.04%)
Goldman Sachs International Tax-Managed Equity Fund Class R6 (GHTRX)
| Previous Close | 10.54 |
| YTD Return | -16.11% |
| Expense Ratio (net) | 0.00% |
| Category | Foreign Large Blend |
| Last Cap Gain | 0.00 |
| Morningstar Rating | ★★★★★ |
| Morningstar Risk Rating | Average |
| Sustainability Rating |
| Net Assets | 791.14M |
| Beta (5Y Monthly) | N/A |
| Yield | 3.26% |
| 5y Average Return | N/A |
| Holdings Turnover | 162.00% |
| Last Dividend | 0.00 |
| Average for Category | N/A |
| Inception Date | Apr 30, 2018 |
- GlobeNewswire
Galapagos creates new subscription right plans
Mechelen, Belgium; 6 May 2022, 22.01 CET; regulated information –– Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its board of directors created 2,326,025 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 6 May 2022, the board of directors of Galapagos approved “Subscription Right Plan 2022 BE”, intended for members of personnel of the company and its Belgian subsidiary, “Subscription Ri
- GlobeNewswire
Galapagos demonstrates regulatory and commercial progress in Q1 2022
First three months 2022 financial results: Jyseleca® net sales reached €14.4 millionGroup revenues +20% to €136.3 millionOperating loss -58% to €21.1 millionCash and current financial investments of €4.6 billion on 31 March 2022 Jyseleca approved in Great Britain and Japan for the treatment of ulcerative colitis (UC); commercial roll-out in the EU in rheumatoid arthritis (RA) and UC progressing well with 15 countries reimbursed for RADr. Paul Stoffelsi appointed as Chief Executive Officer (CEO),
